[Recent changes in the therapeutic strategy for NSCLC in association with new anti-cancer agents]

Area of Science:

• Oncology
• Pharmacology

Background:

• Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) have historically received different treatments.
• Recent advancements necessitate subtype-specific treatment strategies for NSCLC, driven by molecular-targeted drugs.

Purpose of the Study:

• To review the evolving therapeutic strategies for NSCLC.
• To characterize targeted gene alterations and evaluate the efficacy of targeted therapies in NSCLC.

Main Methods:

• Review of current literature on NSCLC treatment modalities.
• Analysis of drug efficacy based on histological subtypes and genetic mutations.
• Examination of contraindications for specific drugs like Bevacizumab.

Main Results:

• Bevacizumab has contraindications for squamous cell carcinoma with hemoptysis history.
• Pemetrexed shows efficacy in NSCLC, particularly benefiting adenocarcinoma patients.
• Tyrosine kinase inhibitors are effective when specific gene alterations (EGFR, ALK) are present, primarily in adenocarcinoma.

Conclusions:

• Current NSCLC therapeutic strategies are increasingly based on histological subtype and molecular profiling (EGFR, ALK status).
• Histological and molecular characteristics are crucial for optimizing NSCLC treatment selection and improving patient prognosis.